Search
PRX-OTC
go.drugbank.com/drugs/DB17680ExperimentalPRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.
SPL23-2
go.drugbank.com/drugs/DB17866ExperimentalSPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]
TTX-MC138
go.drugbank.com/drugs/DB18628InvestigationalTTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.
ISF402
go.drugbank.com/drugs/DB06315ExperimentalISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.
Milveterol
go.drugbank.com/drugs/DB05043InvestigationalGSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Cipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigational[L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated
DR-01
go.drugbank.com/drugs/DB18258InvestigationalDR-01 is a monoclonal antibody directed against human CD94.
Toluene
go.drugbank.com/drugs/DB11558InvestigationalVet approvedToluene is a colorless, liquid that is immiscible in water. It is a mono-substituted benzene derivative used in veterinary medicine as a treatment for various parasites in dogs and cats.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesAVAC
go.drugbank.com/drugs/DB05441Experimental[Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate
GC012F
go.drugbank.com/drugs/DB22406InvestigationalGC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).